Search Result

Results for "

ENL

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) c-Myc (2) Epigenetic Reader Domain (14) Histone Methyltransferase (2) HOXA (1) Ligands for Target Protein for PROTAC (1) Molecular Glues (1) PROTACs (4) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cancer (15)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162350

TDI-11055	Epigenetic Reader Domain Apoptosis	Cancer
TDI-11055 is a selective and orally active eleven-nineteen leukemia (ENL) inhibitor, which displaces ENL from chromatin by blocking its YEATS domain interaction with acylated histones. TDI-11055 inhibits ENL and AF9 YEATS domains with IC₅₀ values of 50 nM and 70 nM, respectively, and no activity against GAS41 or YEATS2. TDI-11055 decreases chromatin occupancy of ENL-associated complexes, impairs transcription elongation, suppresses key oncogenic gene expression programs, and induces differentiation. TDI-11055 can be used for the research of acute myeloid leukemia .

HY-145409

SR-0813	Epigenetic Reader Domain	Cancer
SR-0813 is a potent and selective ENL/AF9 YEATS domain inhibitor. SR-0813 has IC₅₀ and EC₅₀ values of 25 nM and 205 nM for ENL YEATS domain, respectively. SR-0813 has IC₅₀ and EC₅₀ values of 311 nM and 76 nM (CETSA) for AF9 YEATS domain, respectively. SR-0813 binds MAP3K19 with over 100-fold lower affinity (K_d=3.5 μM) than ENL YEATS (K_d=30 nM). SR-0813 can be used for the research of acute leukemia .

HY-115881

SR-1114	PROTACs Epigenetic Reader Domain	Cancer
SR-1114 is a PROTAC degrader targeting *ENL. SR-1114 degrades ENL* in a CRBN-dependent manner and selectively downregulates *ENL* target genes. SR-1114 can promote the differentiation of acute myeloid leukemia cells. SR-1114 can be used in tumor research. (Pink: ENL ligand (HY-145409); Black: Linker; Blue: E3 Ligand (HY-14658)) .

HY-169093

MS41	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
MS41 is a selective eleven-nineteen leukemia (ENL) PROTAC degrader, with DC₅₀s of 3.50 nM (MV4;11), 2.84 nM (SEMK2), 3.03 nM (Jurkat), and 26.58 nM (KASUMI1), respectively. MS41 effectively inhibits the growth of ENL-dependent leukemia cells, induces G1 cell cycle arrest and increases apoptosis. MS41 reduces the chromatin occupancy of ENL-associated transcription elongation machinery, and suppresses oncogenic gene expression and leukemia progression. Red: ENL ligand (HY-169094). Black: linker (HY-W105744). Blue: VHL ligand (HY-112078) .

HY-173631

(S)-dHTC1	PROTACs	Cancer
(S)-dHTC1 is a molecular glue degrader targeting the transcriptional co-activator *ENL. (S)-dHTC1 binds the ligase with high affinity only after forming the ENL:dHTC1 complex with an IC₅₀* value of 93 nM. (S)-dHTC1 degrades ENL in MV4;11 cells with a DC₅₀ value of 26 nM. (S)-dHTC1 can be used for acute myeloid leukemia study .

HY-178172

*AF9/ENL-DOT1L PPI-IN-1*	Histone Methyltransferase c-Myc Epigenetic Reader Domain HOXA	Cancer
AF9/ENL-DOT1L/AF4 PPI-IN-1 is a potent *AF9/ENL* and histone methyltransferase DOT1L/AF4 protein-protein interactions (PPI) inhibitor. AF9/ENL-DOT1L/AF4 PPI-IN-1 can inhibit the AF9-DOT1L (IC₅₀ = 1.5 μM), AF9-AF4 (IC₅₀ = 1 μM), ENL-AF4 (IC₅₀ = 1.2 μM) interactions. AF9/ENL-DOT1L/AF4 PPI-IN-1 can suppress the expression of Mixed lineage leukemia (MLL) target genes Myc and Meis1 and selectively block the proliferation of MLL-r and several other leukemia cells. AF9/ENL-DOT1L/AF4 PPI-IN-1 exhibits significant antitumor activities in a mouse model of MLL-r leukemia without overt toxicities. AF9/ENL-DOT1L/AF4 PPI-IN-1 can be used for the study of MLL-r leukemia .

HY-169094

PFI-6-COOH	Epigenetic Reader Domain Ligands for Target Protein for PROTAC	Cancer
PFI-6-COOH (Compound 18) is an *eleven-nineteen leukemia (ENL) ligand, and can be used for synthesis of MS41 (HY-169093), an ENL* PROTAC degrader .

HY-169937

(R)-SR-C-107	Epigenetic Reader Domain	Cancer
(R)-SR-C-107 is an orally available inhibitor of *ENL* (YEAST domain-containing protein) designed to target acute myeloid leukemia (AML). (R)-SR-C-107 targets ENL with IC₅₀ and K_D of 40 nM and 144 nM, respectively. (R)-SR-C-107 demonstrates in vivo efficacy in a xenograft mouse model of AML, with a tumor regression rate of 45% at a dose of 200 mg/kg (PO; QD) .

HY-146187

Antitumor agent-69	Histone Methyltransferase	Cancer
Antitumor agent-69 (compound 12) is a potent inhibitor of protein-protein interaction between DOT1L and *MLL-AF9/MLL-ENL, with K_is of 9 nM and 109 nM for AF9 and ENL*, respectively. Antitumor agent-69 exhibits anticancer cellular activitiy .

HY-152469

Eleven-Nineteen-Leukemia Protein IN-1	Epigenetic Reader Domain	Cancer
Eleven-Nineteen-Leukemia Protein IN-1 is an inhibitor of ENL YEATS domain with an IC₅₀ value of 14.5 nM. Eleven-Nineteen-Leukemia Protein IN-1 interacts with ENL protein and enhances the thermal stability of ENL protein in vitro .

HY-RS08493

MLLT1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MLLT1 Human Pre-designed siRNA Set A contains three designed siRNAs for MLLT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLLT1 Human Pre-designed siRNA Set A MLLT1 Human Pre-designed siRNA Set A

HY-152471

Eleven-Nineteen-Leukemia Protein IN-3	Epigenetic Reader Domain	Cancer
Eleven-Nineteen-Leukemia Protein IN-3 is an orally active inhibitor of ENL YEATS domain with an IC₅₀ value of 15.4 nM. Eleven-Nineteen-Leukemia Protein IN-3 down-regulates MYC expression through ENL in cells and can enhances the thermal stability of ENL protein in vitro .

HY-152470

Eleven-Nineteen-Leukemia Protein IN-2	Epigenetic Reader Domain	Cancer
Eleven-Nineteen-Leukemia Protein IN-2 (compound 23) is an Eleven-Nineteen-Leukemia Protein (ENL) inhibitor with an IC₅₀ value of 10.7 nM. Eleven-Nineteen-Leukemia Protein IN-2 can be used for the research of leukemia .

HY-183555

MS108	PROTACs Epigenetic Reader Domain	Cancer
MS108 is a selective VHL-based eleven-nineteen leukemia protein (ENL) PROTAC degrader with DC₅₀ of 0.6 nM. MS108 recruits VHL E3 ligase to induce ENL degradation in a VHL- and ubiquitin-proteasome system (UPS)-dependent manner. MS108 degrades the ENL paralog AF9, which shares a highly conserved YEATS domain with ENL. MS108 suppresses proliferation of cancer cells .

HY-183825

Eleven-Nineteen-Leukemia Protein IN-4	Epigenetic Reader Domain c-Myc	Cancer
Eleven-Nineteen-Leukemia Protein IN-4 is a *ENL* YEATS domain inhibitor with an IC₅₀ of 62.0 nM and a K_d of 100.4 nM. Eleven-Nineteen-Leukemia Protein IN-4 downregulates MYC expression and inhibits cancer cell growth; it exerts a synergistic effect with the bromodomain inhibitor JQ-1 (HY-13030). Eleven-Nineteen-Leukemia Protein IN-4 can be used in the research of acute myeloid leukemia .

HY-129224

XS018661	Epigenetic Reader Domain	Cancer
XS018661 is a dual inhibitor of the YEATS domains of ENL and its paralog AF9 with IC₅₀ values of 1.6 and 3 μM as well as K_d values of 754 nM and 523 nM, respectively .

HY-181976

dHTC3	Molecular Glues Epigenetic Reader Domain	Others
dHTC3 is a selective BRD4 molecular glue degrader. dHTC3 specifically recruits the first bromodomain of BRD4 to the E3 ubiquitin ligase complex (SCF ^FBXO3), thereby triggering the ubiquitination and degradation of BRD4 .

MLLT1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
MLLT1 Human Pre-designed siRNA Set A contains three designed siRNAs for MLLT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.